Autoimmune and autoinflammatory diseases result from complex interplay of genetic, environmental, and immunological factors and affect millions of people worldwide. Advances in genetics, disease modeling, immune monitoring and drug development are contributing to the identification of effective drug targets. Therapeutic choices still rely, however, on clinical phenotypes that may not reflect underlying molecular heterogeneity of disease. This results in “trial and error” strategies that delay disease remission, contribute to cumulative tissue damage, and inflate health care costs. We envision a Symposium that will bring together a multidisciplinary group of experts in basic science, translational research, and clinical studies and will address the following themes: 1. Basic mechanisms, with a focus on nucleic acid sensing-dependent inflammation, advances in the study of innate and adaptive immune cells and of multi-cellular platforms and tissues. 2. Systems biology and immune monitoring approaches towards patient stratification and disease-specific target identification. 3. Pre-clinical studies, with an emphasis on organoid biology towards human disease modeling, as well as murine models tailored to reproduce human disease. 4. The latest approaches to design and deliver effective and safe targeted therapies. Through the conference, we expect to gain new scientific knowledge and foster collaborations towards developing quality preclinical research models, recognizing disease subtypes, and identifying biomarkers for early diagnosis, all of which remain significant challenges. This meeting will feature a Career Roundtable, where trainees and early-career investigators will have the opportunity to interact with field leaders from across academic and industry sectors for essential career development advice and networking opportunities.